Karyopharm Therapeutics Inc. Stock Analysis & AI Score
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Karyopharm Therapeutics Inc. (KPTI) holds an ST Score of 48.6 out of 100 (C+), with its strongest factor being Growth (A) and its weakest Momentum (D+). Analysts rate KPTI Buy across 20 ratings with a $9.50 average price target (+4.1% vs the current $1.86).
- Strongest
- GrowthA
- Weakest
- MomentumD+
All factor grades
- GrowthA
- ForecastB+
- ProfitabilityB
- ValuationC
- Financial StrengthC-
- MomentumD+
- Piotroski2/9
Contact
KPTI stock: frequently asked questions
What is KPTI's ST Score?
Karyopharm Therapeutics Inc. (KPTI) has an ST Score of 48.6 out of 100, an overall grade of C+. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is KPTI a buy, sell, or hold?
Wall Street's consensus rating on KPTI is Buy based on 20 analyst ratings. Our own ST Score grades it C+ (48.6/100). This is data, not investment advice — always do your own research.
What is KPTI's valuation grade?
Karyopharm Therapeutics Inc. (KPTI) earns a valuation grade of C, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is KPTI's growth grade?
Karyopharm Therapeutics Inc. (KPTI) earns a growth grade of A, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is KPTI's profitability grade?
Karyopharm Therapeutics Inc. (KPTI) earns a profitability grade of B, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is KPTI's financial strength grade?
Karyopharm Therapeutics Inc. (KPTI) earns a financial strength grade of C-, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for KPTI?
The average analyst price target for Karyopharm Therapeutics Inc. (KPTI) is $9.50 from 20 analysts, which is +4.1% versus the recent price of $1.86.
What is KPTI's Piotroski score?
Karyopharm Therapeutics Inc. (KPTI) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.